FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to the production of chimeric antigen receptors (CAR), referred to as multi-chain CARs, and can be used in medicine for antitumor therapy. Multi-chain CAR is directed against a cell surface marker represented on a target cell and comprises two non-covalently linked transmembrane polypeptides. Disclosed CAR structure provides optimal signal transmission. First transmembrane polypeptide comprises a transmembrane domain and a single-chain antibody fragment (scFv) which is capable of binding to a cell surface marker represented on the target cell. Second transmembrane polypeptide comprises a transmembrane domain and a signaling domain.
EFFECT: invention makes it possible to obtain CAR which redirects immune cell specificity and reactivity toward a selected target exploiting ligand-binding domain properties.
22 cl, 26 dwg, 15 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR CONSTRUCTING ALLOGENIC AND HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2736616C2 |
| METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
| METHODS FOR CONSTRUCTING HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2725542C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
| METHOD OF CONSTRUCTING ALLOGENIC AND DRUG RESISTANT T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2689558C1 |
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
| CD33-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2701341C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| EXPRESSION OF NEW CELL MARKS | 2018 |
|
RU2796334C2 |
